METTL5 and cancer: The results of METTL5 expression in cancer and paracancerous tissues based on immunohistomicroarrays of 80 cases showed that the same expression of METTL5 was upregulated in HCC (p < 0.01) (Figure 1B), and to assess the effect of METTL5 on survival prognosis, METTL5 expression levels were compared between patients in high‐ and low‐expression groups, results showed that high‐expression patients had a shorter OS and DFS than low‐expression patients (Figure 1E,F).